Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech (AIM) recently presented data at the British Society for Immunology Congress 2022 regarding the safety and efficacy of its intranasal treatment, Ampligen (rintatolimod). The study found that Ampligen was well-tolerated among healthy subjects, with no severe adverse events reported. The treatment potentially inhibits respiratory viruses, including SARS-CoV-2. Results indicated positive immune responses and support further development of Ampligen as a prophylactic option for respiratory infections.

AIM ImmunoTech Inc. (NYSE American: AIM) announced its abstract acceptance for poster presentation at the British Society for Immunology Congress 2022, scheduled for December 5-8, 2022, in Liverpool, UK. The poster, titled Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen, will be presented by Lisanne C.A. Smidt on December 7. Ampligen is currently in clinical trials for various conditions, including pancreatic cancer and COVID-19-related syndromes.

AIM ImmunoTech Inc. (NYSE American: AIM) reported its Q3 2022 financial results, noting a cash position of $36.7 million, sufficient for operations through 2023. The company is advancing multiple clinical studies for its lead product, Ampligen (rintatolimod), targeting various cancers and ailments, including COVID-19. Key updates include positive trial data for Ampligen in triple-negative breast cancer and FDA clearance for a Phase 2 study on post-COVID conditions. AIM is focused on reaching clinical milestones while managing operating losses, which increased to $6.4 million in Q3 2022.

AIM ImmunoTech Inc. (AIM) announced positive data from a Phase 1 study of Ampligen as part of a CKM regimen for early-stage triple negative breast cancer (TNBC). Results presented at the SITC 37th Annual Meeting show a pathologic complete response (pCR) rate of 56%, comparable to pembrolizumab-based treatments. The regimen, combining Ampligen, interferon-α2b, and celecoxib, was well tolerated with no dose-limiting toxicities. A Phase 2 study is planned to further evaluate Ampligen's efficacy as an alternative therapy.

AIM ImmunoTech Inc. announced plans to enhance its corporate governance by adding two directors with expertise in biotechnology commercialization and diversity. The board's Compensation Committee will consult an independent compensation expert to review executive pay, responding to shareholder feedback on past advisory votes.

In the previous year, AIM achieved significant clinical milestones, including positive outcomes in pancreatic cancer and other studies involving its lead product, Ampligen. These advancements aim to further align leadership with shareholder interests and boost AIM's value.

AIM ImmunoTech Inc. (AIM) announced the re-election of all three directors at its Annual Meeting of Shareholders. Directors Stewart Appelrouth, Thomas Equels, and William Mitchell received unanimous support. The company expressed gratitude towards shareholders and reaffirmed its commitment to advancing its lead drug, Ampligen, into oncology for long-term shareholder value. Ampligen is currently in clinical trials for various cancers and is approved in Argentina for chronic fatigue syndrome.

AIM ImmunoTech Inc. has received FDA Orphan Drug Designation for its immuno-modulator, Ampligen^® (rintatolimod), targeting Ebola virus disease. This designation acknowledges Ampligen's potential in treating rare diseases, qualifying AIM for incentives like tax credits and possible market exclusivity. Although Ebola isn't a current primary focus, previous studies show Ampligen's efficacy against various viruses, including COVID-19. The firm is conducting ongoing clinical trials to further evaluate Ampligen's applications.

AIM ImmunoTech Inc. announced that the Delaware Court of Chancery denied Jonathan Jorgl's request for a preliminary injunction regarding his attempts to nominate directors to AIM's Board. The Court found Jorgl's nomination notice misleading and non-compliant with AIM's bylaws. Consequently, Jorgl's nominations will not be recognized in the upcoming Annual Meeting set for November 3, 2022. AIM urges shareholders to support the current Board, highlighting ongoing progress in clinical trials and the company’s efforts in oncology.

AIM ImmunoTech Inc. has issued a letter to shareholders addressing misleading statements from an activist group attempting to gain control of the Board. The letter emphasizes that the group is led by Franz Tudor, a convicted felon, and funded by Michael Xirinachs, also a convicted criminal. AIM urges shareholders to support their current directors in the upcoming November 3, 2022 Annual Meeting. The Board highlights significant positive developments, including positive clinical trial results and lifting of an FDA Clinical Hold.